LNP-Based Delivery of CRISPR/Cas9: Optimization of RNP and mRNA Modalities

Introduction to LNP-Based CRISPR/Cas9 Delivery

With the rapid advancement of precision medicine and gene therapy, the safe and efficient delivery of the CRISPR/Cas9 system into target cell nuclei has emerged as a critical challenge for translating preclinical research into practical applications. While viral vectors (e.g., AAV, Lentivirus) face limitations such as potential immunogenicity, genomic integration risk, and restricted payload capacity, lipid nanoparticles (LNPs) have established themselves as leading non-viral delivery platforms due to their excellent biocompatibility, tunable pharmacokinetics, and superior tissue-targeting capabilities.

LNPs are nanoscale structures composed of ionizable lipids, cholesterol, helper lipids, and PEGylated lipids. They encapsulate negatively charged nucleic acids in the core through a combination of electrostatic and hydrophobic interactions. In gene editing, LNPs typically deliver either RNPs (ribonucleoprotein complexes) or mRNA encoding Cas9. The choice between these modalities fundamentally influences the kinetic behavior, intracellular residence time, and overall editing efficiency of the system, directly impacting specificity and off-target control.

Why Efficient Delivery Is Foundational for Gene Editing?

Gene editing relies on precise modification of genetic material, and delivery efficiency directly dictates success rates and translational potential.

Kinetic control of off-target effects: Ideal gene editing relies on transient expression. LNP-delivered nucleic acids degrade rapidly after completing their function. Compared with long-term expression from viral vectors, this transient profile limits the intracellular window of active Cas9, minimizing off-target effects.

Pharmacokinetics and targeting: By fine-tuning the lipid composition of LNPs—particularly the pKa of ionizable lipids (typically optimized between 6.2–6.5)—researchers can exploit endogenous protein adsorption (e.g., ApoE) to achieve precise tissue targeting, such as the liver, or apply surface ligands for organ-specific delivery.

Overcoming endosomal barriers: A key bottleneck in delivery is endosomal escape. After uptake, LNPs are sequestered in endosomes; without efficient disruption, nucleic acids are directed to lysosomal degradation. High-performing LNPs rapidly protonate in acidic endosomal conditions, trigger membrane fusion, and release their cargo effectively.

Key Factors Affecting LNP Performance for CRISPR/Cas9

The delivery efficiency of LNPs is not incidental but the result of precise engineering of their physicochemical properties. From the stability of the core nucleic acid cargo to intracellular release mechanisms, every physical parameter directly impacts CRISPR/Cas9 editing efficiency and overall safety. Understanding and optimizing the following key factors is essential for translating experimental designs into high-performance delivery systems.

Lipid Composition and Structure: Functional Modular Design

LNP performance is fundamentally determined by its four-component chemical composition, with each lipid playing a distinct role in structural stability and biological activity.

Ionizable Lipids: These are the core functional component of LNPs. The tertiary or quaternary amine groups enable protonation under acidic endosomal conditions (pH < 6.0), a critical trigger for membrane fusion and cytosolic release. The pKa of ionizable lipids is a key lever for balancing delivery efficiency and cytotoxicity.

Helper Lipids: Neutral phospholipids, such as DSPC or DOPE, provide structural support and regulate membrane fluidity and endosomal disruption. Lipids like DOPE, with strong non-bilayer tendencies, enhance membrane fusion by inducing phase transitions from lamellar to inverted hexagonal structures.

Cholesterol: By modulating lipid packing density, cholesterol improves particle rigidity and prevents premature leakage of cargo in complex biological fluids.

PEGylated Lipids: Hydrophilic PEG chains create steric hindrance, reducing non-specific protein adsorption and extending circulation time. PEG content must be carefully balanced to avoid the "PEG dilemma," which can impede cellular uptake.

Table.1 Key Physicochemical Parameters of LNPs and Their Impact on Delivery Performance.

Particle Size, Charge, and Surface Properties

The physical form and surface characteristics of LNPs are among the most critical determinants of their in vivo behavior, directly influencing tissue distribution, cellular uptake efficiency, and overall delivery performance. Optimizing these parameters is essential to achieve consistent, reproducible results in gene editing applications.

Particle Size

For systemic administration, LNPs are generally engineered to have diameters between 50 and 100 nm. Particles above this range are more likely to be rapidly sequestered and cleared by the liver and spleen through the reticuloendothelial system (RES), which can significantly reduce delivery efficiency to target tissues. Conversely, particles smaller than 50 nm may face limitations in payload capacity or be rapidly eliminated via renal filtration, reducing their functional bioavailability. In addition to absolute size, the particle size distribution, often quantified by the polydispersity index (PDI), is critical: a PDI below 0.2 is typically required to ensure uniformity and reproducibility across batches, minimizing variability in uptake and intracellular release. Controlling particle size precisely also facilitates predictable tissue penetration and allows for tailored biodistribution profiles depending on the therapeutic target.

Surface Charge and Zeta Potential

LNPs are designed to maintain a near-neutral or slightly positive surface charge at physiological pH (~7.4). This balance minimizes non-specific interactions with serum proteins, preventing rapid clearance and reducing unintended immune activation. Once internalized into acidic endosomal compartments, the ionizable lipids within the LNP rapidly protonate, resulting in a strong positive surface charge. This charge shift enhances electrostatic interactions with the negatively charged endosomal membrane, promoting membrane destabilization, fusion, and efficient release of the nucleic acid payload into the cytoplasm. The precise control of surface charge dynamics is therefore central to maximizing intracellular delivery while maintaining overall biocompatibility.

Encapsulation Efficiency and Payload Capacity

N/P Ratio: The assembly of LNPs relies on electrostatic interactions between cationic lipid amines (N) and nucleic acid phosphate groups (P). The N/P ratio is a key design parameter: if the ratio is too low, nucleic acids remain insufficiently complexed and are vulnerable to rapid degradation in the extracellular environment. Conversely, an excessively high ratio may enhance encapsulation but can also increase cytotoxicity and disrupt particle stability. Fine-tuning this ratio is critical to ensure both high payload retention and safe cellular delivery.

Microfluidic Mixing: Advanced microfluidic techniques allow precise control over the FRR and total flow rate (TFR) during LNP formation. This rapid mixing of lipid and nucleic acid phases occurs on the millisecond timescale, promoting the formation of a stable, homogeneous lipid-nucleic acid core. Efficient microfluidic mixing not only reduces particle size variability but also improves reproducibility and scalability of LNP production, which is essential for both experimental consistency and potential large-scale manufacturing.

Payload Limits: The maximum cargo capacity of LNPs is determined by the balance between lipid-to-nucleic acid mass ratios and particle assembly quality. Overloading particles can compromise structural integrity, while underloading reduces delivery efficiency. By carefully adjusting the mass ratio, researchers can optimize the payload-to-carrier balance, ensuring that each batch of LNPs delivers consistent bioactivity and maintains the desired kinetic and functional properties. This optimization is a critical step for achieving predictable gene editing outcomes across different experimental and production scales.

Optimization Strategies for mRNA Delivery

Optimizing mRNA delivery systems focuses on overcoming multiple biological barriers to achieve "high protection, low immunogenicity, and efficient translation." mRNA molecules are inherently unstable and potentially immunogenic. Through precise sequence engineering and chemical modifications, fragile mRNA can be converted into a robust "instruction carrier," extending its functional persistence in the cytoplasm and maximizing protein translation, forming a solid foundation for efficient CRISPR/Cas9 activity.

Protecting mRNA from Degradation

Once delivered into the cytoplasm, mRNA that lacks sufficient protection is immediately exposed to the cell's innate surveillance mechanisms. Pattern recognition receptors (PRRs), such as TLR7/8 and RIG-I, can detect unmodified RNA, while RNases actively degrade exposed sequences. This degradation not only reduces the availability of mRNA for Cas9 translation but also triggers stress pathways and type I interferon responses, which can compromise cell health and viability. Designing mRNA with protective strategies at multiple molecular levels is therefore essential to ensure sustained translation and functional activity.

Nucleotide Chemical Modifications: Incorporating modified nucleotides, such as N1-methylpseudouridine or 5-methoxyuridine, during in vitro transcription (IVT) partially or fully replaces natural uridines. These modifications reduce immunogenicity, prevent PRR recognition, and extend mRNA half-life. Fully modified mRNA can achieve 3–5× longer cytoplasmic persistence, providing a sufficient window for repeated or continuous Cas9 translation. Such modifications fundamentally alter the spatial conformation of RNA molecules, helping them evade detection by RIG-I and TLRs, and thereby minimizing unwanted cellular immune activation.

Co-transcriptional Capping and Cap-1 Structures: The 5′-cap is critical for both translation initiation and protection against decapping enzymes. Traditional enzymatic capping methods are often inefficient and can vary between batches. Co-transcriptional capping technologies, such as CleanCap analogs, achieve >95% capping efficiency in a single step, producing natural eukaryotic Cap-1 structures (m7GpppAm). Cap-1 prevents recognition by IFIT proteins, which otherwise identify mRNA as foreign, ensuring uninterrupted translation. This approach provides robust molecular protection while streamlining manufacturing workflows.

UTR Stabilization and GC Enrichment: Both 5′ and 3′ untranslated regions (UTRs) regulate mRNA stability and translation efficiency. Using well-characterized, high-stability UTR sequences from human α-/β-globin or CYBA genes can significantly extend cytoplasmic lifespan. Enriching the overall GC content enhances thermodynamic stability and preserves secondary structures against nuclease activity, further protecting mRNA from premature degradation.

miRNA Target Sequences: Inserting tissue-specific miRNA binding sites into the 3′-UTR provides an advanced layer of "active defense" and off-target control. For example, including a miR-122 binding site can prevent Cas9 expression in liver cells. This ensures that, even if LNP delivery is not perfectly targeted, off-target tissues rapidly degrade the mRNA, improving the safety profile at the molecular level.

Improving Translation Efficiency Post-Delivery

Even when mRNA reaches the cytoplasm intact, achieving high levels of protein translation is critical. Optimizing translation ensures that Cas9 is produced efficiently, accurately, and for a sufficient duration, which is often the limiting factor for gene editing experiments.

Segmented Poly(A) Tail Design: The poly(A) tail plays a dual role in nuclear export and translation initiation by interacting with poly(A)-binding proteins (PABP) to facilitate ribosome recruitment. Maintaining a tail length of 120–150 nucleotides maximizes translation efficiency. Advanced designs segment the poly(A) tail with short non-adenosine linkers (e.g., GCA sequences), which reduce susceptibility to deadenylase enzymes such as PAN2/PAN3, thereby extending the active translation window.

Codon Optimization and 5′-UTR Structural Relaxation: Codon usage bias differs between cell types, and matching codons to the host tRNA pool can prevent ribosome stalling, increase translation speed, and improve protein assembly. Additionally, minimizing secondary structures near the 5′-UTR and start codon reduces scanning resistance for the 43S pre-initiation complex, allowing more efficient translation initiation. This fine-tuning ensures that even large proteins like Cas9 are synthesized reliably.

Kozak Sequence Optimization: Cas9, derived from bacterial systems, often expresses poorly in eukaryotic cells without proper translation initiation signals. Embedding a strong Kozak consensus sequence (e.g., GCCACCATGG) immediately upstream of the AUG start codon enhances ribosome recognition and binding, significantly boosting translation efficiency.

Circular RNA (circRNA) for Extended Translation: For applications requiring sustained Cas9 expression, linear mRNA is often insufficient. CircRNA, generated by covalently closing the ends of mRNA, eliminates free termini that are susceptible to exonucleases. Combined with internal ribosome entry sites (IRES), circRNA enables continuous protein production over days or even weeks at low delivery doses, providing a highly efficient solution for complex or multiplexed gene editing experiments.

Applications of LNP-Based CRISPR Delivery

When the physicochemical properties of LNPs are perfectly matched with the characteristics of CRISPR/Cas9 payloads, this delivery platform demonstrates transformative potential in research and preclinical studies. Compared with traditional electroporation or viral vectors, LNPs offer rapid action, low cytotoxicity, and scalable production, reshaping the boundaries of basic biological research and novel therapeutic development. The following are three representative research applications of LNP-mediated CRISPR delivery.

Gene Knockout in Animal Models

In basic research, generating specific gene knockout (KO) animal models has traditionally relied on labor-intensive embryonic stem cell targeting or lengthy breeding workflows. LNP delivery of CRISPR/Cas9 now provides researchers with a ready-to-use in vivo gene editing tool. Leveraging LNPs' natural liver tropism—mediated primarily by ApoE adsorption in circulation and subsequent binding to low-density lipoprotein receptors on hepatocytes—researchers can achieve efficient liver-specific gene knockout in mice or non-human primate models via conventional intravenous injection. This approach avoids the genomic instability risks associated with viral vectors and significantly shortens the timeline for disease model construction, enabling rapid validation of disease-driving genes and early phenotypic studies. For such in vivo model applications, BOC Sciences offers one-stop support, including liver-targeted LNP formulation screening, high-quality nucleic acid encapsulation, custom in vivo delivery verification, and target tissue editing efficiency assessment.

Immune Cell Engineering

In ex vivo engineering of immune cells (such as primary T cells, NK cells, or macrophages), traditional viral transduction or electroporation methods often result in high cytotoxicity, low proliferation, and uncontrolled genomic off-target effects. The extreme sensitivity of primary cells makes LNPs a gentler and highly efficient alternative. In developing next-generation allogeneic "off-the-shelf" cell therapies, researchers often need to simultaneously knock out multiple endogenous genes (e.g., TCRα, HLA molecules, or PD-1) to reduce graft-versus-host reactions and enhance cytotoxic activity. Using LNPs to co-deliver Cas9 mRNA and multiple sgRNAs allows for high-efficiency multiplexed gene knockout while maintaining primary cell viability and proliferation, providing a highly controllable platform for functional remodeling of complex immune cells. BOC Sciences can assist with optimizing LNP transfection efficiency for primary cells, analyzing endocytic uptake mechanisms of the complexes, and conducting comprehensive in vitro functional assessments.

Targeted Therapeutic Delivery

Moving beyond liver-targeted delivery to precise delivery to extrahepatic tissues—such as the lungs, spleen, or tumor microenvironments—is a frontier in LNP-CRISPR research. Scientists are exploring sophisticated nanoparticle surface engineering, including selective organ targeting (SORT) lipid strategies, to control the protein corona and exploit endogenous uptake mechanisms for precise delivery to specific tissues or cell populations. This targeting capability greatly expands the research potential of CRISPR, reducing off-target effects and enabling gene editing interventions to act effectively within disease-relevant tissues. For these advanced targeting applications, BOC Sciences provides custom functional lipid libraries, targeted particle surface modification, high-precision microfluidic encapsulation, and multidimensional in vitro and in vivo distribution characterization services.